With the implementation and advancement of the new version of the Drug Administration Law and the tightening of the supervision of the pharmaceutical industry, a large number of pharmaceutical companies' illegal sales of inferior drugs and illegal operations are being exposed one after another, which continues to wake up the industry
.
It is reported that since December, many pharmaceutical companies have been announced and fined
for producing and selling counterfeit drugs, failing to comply with the quality management practices of drug sales, and failing to correct problems.
On December 16, the Yunnan Provincial Food and Drug Administration announced the 2022 administrative penalty information disclosure data (Part 18).
According to the clue report of the Yunnan Provincial Food and Drug Inspection Center, a certain Chinese medicine pieces Co.
, Ltd.
in Baoshan produced and operated toxic pieces without authorization, and failed to comply with the "Good Manufacturing Practice" to produce Chinese medicine pieces, was warned, confiscated toxic pieces, and fined 42,600 yuan
.
On December 14, the Shandong Food and Drug Administration issued a notice on the results of the random inspection of drug quality (No.
3 of 2022), which involved a total of 4 batches of drugs produced by 3 enterprises in this phase of the sampling inspection that did not meet the regulations, among which the content determination of 2 batches of lactase raw tablets produced by a pharmaceutical company in Shandong did not meet the regulations
.
On December 12, a pharmaceutical company in Northeast China issued an announcement that it received the Administrative Penalty Notice issued by the Liaoning Provincial Administration for Market Regulation on December 9
, 2022.
The Liaoning Provincial Municipal Supervision Bureau held that the company's sale of L-carnitine APIs at an unfairly high price violated the Anti-Monopoly Law and constituted an abuse of market dominance to sell goods at unfairly high prices
.
According to relevant regulations, the Liaoning Provincial Administration for Market Regulation imposed a lighter penalty on the company, and intends to impose a fine of 2% of China's domestic sales in 2018, totaling 133 million yuan
.
On December 8, a pharmaceutical company in Jilin issued an announcement that on the same day, the company received the "Prior Notice of Administrative Punishment" from the Jilin Securities Regulatory Bureau, and due to suspected information disclosure violations and violations, the Jilin Securities Regulatory Bureau planned to decide to give the company and relevant responsible persons a warning and a total fine of 3.
9 million yuan
.
According to the announcement information, the pharmaceutical company was fined for violating the letter disclosure regulations, and between August 2020 and April 2021, the company and its subsidiaries had six major lawsuits, but it was not until April 24, 2021 that the company issued an announcement disclosing the above six major litigation matters
.
It is worth mentioning that in addition to the frequent fines imposed on pharmaceutical companies, there have been many
recent cases of medical device companies being punished for the production, sales and use of unqualified medical devices.
For example, recently, the website of the Shenzhen Market Supervision Bureau disclosed a news
that a company was fined more than 160,000 yuan for producing Class II medical devices that did not meet the technical requirements of the product.
Prior to this, an administrative penalty information published on the website of the Hunan Provincial Drug Administration showed that a medical protective mask produced by a medical device company in Hunan that did not meet the requirements of mandatory standards had also been fined
720,000 yuan.
Industry analysts believe that from the frequent fines of many pharmaceutical companies, the current pharmaceutical industry's attention to product quality, sales and other specifications is constantly increasing, and the corresponding supervision is becoming more and more stringent
.
In this context, for enterprises, only by standardizing operations, continuously improving product quality, and strictly abiding by relevant laws and regulations can they better "survive
".
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
